Mission

EATRIS transforms scientific discoveries into innovative and high impact medicines, diagnostics and medical devices through European collaborative consortia of academic, industrial and governmental partners.
Approach to the Mission

Assemble the resources of the Academic Centres of Excellence to create a virtual Centre of Translation Medicine
Nine European countries are participating in 2012.
European collaborative consortia

Governments
- Access to regulatory agencies
- Resources to support critical infrastructure
- Coordination & dialogue among EU countries
- Long-term vision for improved, cost-effective patient care

Academia
- Fundamental discoveries
- Excellent pre-clinical development
- Excellent research infrastructure
- Translational expertise
- Access to patients, clinical experts

Industry
- Excellence in clinical development
- Understanding of market mechanisms
- Resources to enter risky clinical phase
- Production
- Global reach in distribution & sales

To produce better patient outcomes

Leveraging the combined power of stakeholders

EATRIS
European Infrastructure for Translational Medicine
An European effort coordinated in Amsterdam

Leveraging expertise
The organizational 3D matrix

Horizontal & vertical expertise / diseases

Expert group

- Clinical Affairs
- Training
- Dissemination
- QA/QC
- Regulatory
- IP, contracts
- Access
- Financing
- Communication

Product group

Diseases

EATRIS
European Infrastructure for Translational Medicine
Five Product Groups

- Biomarkers Group & consortia
- Vaccine Group & consortia
- Tracer & Imaging Group & consortia
- ATMP’s Group & consortia
- Small Molecules Group & consortia

Drivers of scientific excellence
Each Product Group:

- Drives the scientific strategy and content of the translational consortia
- Comprises of leading scientists from participating centers and countries
- Define the total package of services offered, communication literature, best practice sharing within and across product groups, aligned with Medical Sciences Research Infrastructure.
- Focuses on quality (priority to benchmarking and best practice sharing)
- Offers complete range of relevant services and capacities
- Manages projects in the ‘product’ area.
Supporting Expert Teams

- Clinical Affairs
- Training Dissemination
- QA/QC Regulatory
- Access
- Legal affair IP, contracts
- Financing Communication

→ Expert advisors support and expertise feeds into Product Groups
Expert Teams:

To support Product Groups/consortia with their expertise on strategy, planning en product development to ensure:

- “One-Stop Shop” single access port
- Clinical expertise
- Project, administrative & financial management
- Expertise on regulatory & legal affairs
- Quality assurance
- IP & technology transfer
- Project-tailored development teams
- Development plan/milestones/timelines
Key Value Points for the EU Translational Medicine

- “One-Stop Shop”
- Cross border access to centres of excellence: academia and patients (clinicians)
- Improved technology models and methods
- Regulatory request compliant
- Unmet diseases: i.e. “non economical” or rare diseases
- Bringing translational knowledge to academia
- Not for profit though co-creating value for public health society
- Cost control for new treatments ....
Key Value Points for the single national network

- “One-Stop Shop” *Centralised offering and access with “non scientific” support*
- Synergy of the offering: access to academia and patients (clinicians) are shared to offer a “full service”
- Improved technology and methods through exchange and common development
- QA/QC Harmonization: toward an European standard of Regulatory compliance
- Unitary Approach to Unmet Diseases: i.e “non economical” or rare diseases
- Bringing translational knowledge to academia

**It results in:**

- Enhanced capacity to obtain funding from focused programs and to answer to calls through preformed networks
- Participation to the national Road Map
- Access to the Translational Medicine Market
EATRIS responded to the FPVII call on the INFRASTRUCTURES INFRA-2012-1.1.5. (Implementation)
Facilities for translational research in medicine
Requested 9.9 m€
I3 (Integrated Infrastructure Initiative)
• (i) Networking activities,
• (ii) Trans-national access and/or service activities (Pilot projects 30% of the funds) and
• (ii) Joint research activities
If funded completely IATRIS will receive 1.5m€